CARsgen Therapeutics Reports 2026 Interim Results
CARsgen Therapeutics Holdings Limited has announced its 2026 interim results. The company also disclosed its cash and cash equivalents as of the reporting period.
CARsgen Therapeutics Holdings Limited (2171.HK) has released its financial results for the first half of 2026. The company specializes in the development of CAR T-cell therapies for cancer treatment.
Key business highlights included reported cash and cash equivalents of approximately RMB 1,400 million as of June 30, 2026. These details were presented in the company's interim report.
The company continues its focus on advancing its pipeline of innovative cancer treatments. Its primary efforts involve the development of CAR T-cell therapies aimed at addressing unmet needs in oncology.
CARsgen Therapeutics has previously reported progress in clinical trials and development programs targeting various forms of cancer, underscoring its commitment to the field.